BioSpecifics Technologies Corp (BSTC) Earns Media Impact Score of 0.24
Media stories about BioSpecifics Technologies Corp (NASDAQ:BSTC) have been trending somewhat positive on Monday, Accern reports. The research group identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. BioSpecifics Technologies Corp earned a daily sentiment score of 0.24 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 85 out of 100, indicating that recent press coverage is very likely to have an impact on the stock’s share price in the near future.
Separately, Zacks Investment Research downgraded BioSpecifics Technologies Corp from a “hold” rating to a “sell” rating in a research report on Monday, May 15th.
BioSpecifics Technologies Corp (BSTC) opened at 51.10 on Monday. The firm’s 50-day moving average price is $50.79 and its 200-day moving average price is $52.71. BioSpecifics Technologies Corp has a 52-week low of $35.79 and a 52-week high of $58.79. The firm has a market cap of $366.44 million, a P/E ratio of 31.35 and a beta of 1.76.
TRADEMARK VIOLATION WARNING: This piece of content was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/07/17/biospecifics-technologies-corp-bstc-earns-media-impact-score-of-0-24.html.
About BioSpecifics Technologies Corp
BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development.
Receive News & Stock Ratings for BioSpecifics Technologies Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies Corp and related stocks with our FREE daily email newsletter.